Abstract
BackgroundVariability in clinical response to B-cell depletion therapy (BCDT) with the anti-CD20 mAb rituximab (RTX) has been well described in Systemic Lupus Erythematosus (SLE). Poor clinical response is associated with...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
